WRBY250117C25000
- 1.19
- -0.54-31.21%
Warby Parker Newsroom
Warby Parker Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)
JMP Securities Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $28
Baird Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $30
Warby Parker Is Maintained at Hold by Stifel
Goldman Sachs Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $26
Warby Parker Is Maintained at Buy by Goldman Sachs
Warby Parker Price Target Raised to $26.00/Share From $20.00 by Goldman Sachs
Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $26
Warby Parker Analyst Ratings
Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $26
Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $22
Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $22
Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $22
A Quick Look at Today's Ratings for Warby Parker(WRBY.US), With a Forecast Between $20 to $23
Warby Parker Is Maintained at Overweight by Piper Sandler
Morgan Stanley Remains a Hold on Warby Parker (WRBY)
Warby Parker Analyst Ratings
A Quick Look at Today's Ratings for Warby Parker(WRBY.US), With a Forecast Between $19 to $23
Warby Parker's Strategic Growth and Financial Performance Earns Buy Rating From Oliver Chen